Tuberculosis (TB) is the biggest killer worldwide of any infectious disease, a situation
worsened by the advent of the HIV epidemic and the emergence of multi-drug resistant …

The tuberculosis (TB) pandemic continues to rampage despite widespread use of the BCG
(Bacillus Calmette–Guérin) vaccine. Novel vaccination strategies are urgently needed to …

TB is presenting new challenges as a global health problem, especially with new threats of
HIV coinfection and multidrug-resistant and extensively drug-resistant strains of …

The current tuberculosis (TB) vaccine Mycobacterium bovis bacillus Calmette-Guérin (BCG)
is the most widely used vaccine worldwide, but it does not prevent the establishment of …

Over the past 50 years, the Mycobacterium bovis bacille Calmette–Guérin (BCG) vaccine
against tuberculosis (TB) has maintained its position as the world's most widely used …

Tuberculosis (TB) vaccine research has reached a unique point in time. Breakthrough
findings in both the basic immunology of Mycobacterium tuberculosis infection and the …

Mycobacterium tuberculosis (M. tb) infection leads to active tuberculosis (TB), a disease that
kills one human every 18 s. Current therapies available to combat TB include chemotherapy …

Eleven new tuberculosis (TB) vaccines are in various phases of clinical trials. These include
subunit vaccines to improve the current vaccine BCG, and recombinant BCG to substitute for …

Effective prophylactic and/or therapeutic vaccination is a key strategy for controlling the
global TB epidemic. The partial effectiveness of the existing TB vaccine, bacille Calmette …

An estimated 2 billion people are latently infected with Mycobacterium tuberculosis, the
majority of which are already BCG vaccinated and repeatedly sensitized to mycobacterial …